Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
$5.30
-1.8%
$4.79
$2.20
$6.20
$194.18M1.5111,620 shs4,758 shs
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$3.82
-2.9%
$3.98
$2.55
$6.42
$196.76M1.142,827 shs2,836 shs
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
$2.59
-3.7%
$3.11
$1.10
$6.01
$46.51M1.6135,901 shs124,647 shs
Organigram Global Inc. stock logo
OGI
Organigram Global
$1.33
-0.7%
$1.40
$0.85
$2.08
$179.60M1.45582,382 shs721,245 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
-1.78%-3.39%-3.03%+32.43%+86.76%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
-0.52%-1.55%+0.26%-10.86%-9.38%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-3.72%-13.67%-21.99%+26.34%+13.10%
Organigram Global Inc. stock logo
OGI
Organigram Global
-0.75%-13.07%-3.62%+15.65%-20.83%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
2.5434 of 5 stars
3.62.00.00.02.60.00.6
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
1.6953 of 5 stars
3.53.00.00.01.90.00.0
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
2.7366 of 5 stars
3.65.00.00.01.30.80.6
Organigram Global Inc. stock logo
OGI
Organigram Global
1.144 of 5 stars
0.02.00.00.02.00.02.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
3.17
Buy$11.00107.39% Upside
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
3.00
Buy$13.00240.76% Upside
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
3.20
Buy$28.501,000.39% Upside
Organigram Global Inc. stock logo
OGI
Organigram Global
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NRXP, GNFT, OGI, and EPRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/24/2025
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$11.00
6/26/2025
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$12.00
6/26/2025
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$12.00
6/20/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00
6/16/2025
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSpeculative Buy
6/6/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00
5/16/2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$31.00 ➝ $31.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
N/AN/AN/AN/AN/AN/A
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$76.77M2.48$0.07 per share56.26$1.50 per share2.54
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
N/AN/AN/AN/A($1.48) per shareN/A
Organigram Global Inc. stock logo
OGI
Organigram Global
$117.47M1.52N/AN/A$2.07 per share0.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
-$25.50M-$0.76N/AN/AN/AN/A-367.73%-112.23%8/6/2025 (Estimated)
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$1.63MN/A0.00N/AN/AN/AN/AN/AN/A
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-$25.13M-$2.01N/AN/AN/AN/AN/A-355.00%8/13/2025 (Estimated)
Organigram Global Inc. stock logo
OGI
Organigram Global
-$33.39M$0.1013.30N/AN/A8.05%-5.93%-4.39%8/13/2025 (Confirmed)

Latest NRXP, GNFT, OGI, and EPRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-$0.31N/AN/AN/AN/AN/A
8/12/2025Q3 2025
Organigram Global Inc. stock logo
OGI
Organigram Global
-$0.01N/AN/AN/A$68.04 millionN/A
8/6/2025N/A
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
-$0.21N/AN/AN/AN/AN/A
5/15/2025Q1 2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-$0.40-$0.34+$0.06-$0.34$1.14 million$1.14 million
5/6/2025Q1 2025
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
-$0.19-$0.21-$0.02-$0.21N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
N/AN/AN/AN/AN/A
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
N/AN/AN/AN/AN/A
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
N/AN/AN/AN/AN/A
Organigram Global Inc. stock logo
OGI
Organigram Global
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
N/A
11.10
11.10
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
0.08
1.23
1.23
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
N/A
0.22
0.22
Organigram Global Inc. stock logo
OGI
Organigram Global
N/A
3.42
1.90

Institutional Ownership

CompanyInstitutional Ownership
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
N/A
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
2.24%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
4.27%
Organigram Global Inc. stock logo
OGI
Organigram Global
34.63%

Insider Ownership

CompanyInsider Ownership
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
N/A
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
4.20%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
19.00%
Organigram Global Inc. stock logo
OGI
Organigram Global
0.09%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
2935.96 millionN/AN/A
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
12050.00 million47.90 millionNot Optionable
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
217.29 million14.00 millionOptionable
Organigram Global Inc. stock logo
OGI
Organigram Global
860134.03 million133.91 millionOptionable

Recent News About These Companies

OGI Organigram Global Inc. - Seeking Alpha

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Eupraxia Pharmaceuticals stock logo

Eupraxia Pharmaceuticals NASDAQ:EPRX

$5.30 -0.10 (-1.78%)
Closing price 08/1/2025 03:50 PM Eastern
Extended Trading
$5.58 +0.27 (+5.18%)
As of 08/1/2025 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

GENFIT stock logo

GENFIT NASDAQ:GNFT

$3.82 -0.12 (-2.93%)
As of 08/1/2025 03:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

NRx Pharmaceuticals stock logo

NRx Pharmaceuticals NASDAQ:NRXP

$2.59 -0.10 (-3.72%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.60 +0.01 (+0.42%)
As of 08/1/2025 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Organigram Global stock logo

Organigram Global NASDAQ:OGI

$1.33 -0.01 (-0.75%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.36 +0.03 (+2.56%)
As of 08/1/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.